According to Consort Medical, Nicoventures, a subsidiary of the British American Tobacco Group, has awarded a contract to Consort's Bespak Division "for the supply of an innovative nicotine inhalation product for use as a safer alternative to smoking." In November 2011, Bespak announced the award of a development contract for scale-up of the "cigarette-like device." … [Read more...] about Bespak to manufacture nicotine inhaler for Nicoventures
Business
Lightlake appoints Kevin Pollack as CFO
Lightlake Therapeutics, which is developing intranasal naloxone to treat eating disorders, has announced the appointment of board member Kevin Pollack as Chief Financial Officer. Pollack joined the board of directors in April 2012. Lightlake Chief Executive Roger Crystal said, "It has been a privilege to work with Kevin since he joined our Board and when we look to … [Read more...] about Lightlake appoints Kevin Pollack as CFO
Hovione and Solvias to collaborate on co-crystals
Inhalation and particle engineering specialist Hovione and Swiss chemical development company Solvias have announced an agreement to collaborate on development and manufacturing of co-crystallized drugs. According to Hovione, "This strengthens Hovione's expertise and experience in overcoming drug delivery challenges and also the supply of GMP materials from phase I to … [Read more...] about Hovione and Solvias to collaborate on co-crystals
FDA issues letter to Alcon over Patanase marketing
The FDA issued a letter to Alcon dated November 13, 2012 regarding a sales aid that the agency says overstates the efficacy of Alcon's Patanase olopatadine hydrochloride nasal spray. In the four-page letter, the agency cites numerous examples of what it says are overstatements of the product's onset of action and the duration of relief and then requests that Alcon … [Read more...] about FDA issues letter to Alcon over Patanase marketing
Unigene says EMA recommendation against calcitonin nasal sprays “catastrophic”
Fortical salmon calcitonin nasal spray manufacturer Unigene says that it is in danger of running out of cash before the end of the first quarter of 2013, due in part to the EMA's July 2012 warning against the use of calcitonin nasal sprays. Unigene President and CEO Ashleigh Palmer said, "The impact of the EMA’s recommendation represents a devastating setback and … [Read more...] about Unigene says EMA recommendation against calcitonin nasal sprays “catastrophic”
Marinomed gets Chinese patent for polymer used in anti-viral nasal spray
Vienna, Austria-based Marinomed has announced the granting of Chinese patent No. CN101678040, titled "Antiviral Polymer," for a component of its Mavirex technology platform. According to the company, the patent covers prevention and treatment of the common cold using the polymer. Marinomed's Coldamaris nasal spray for the common cold is sold over the counter in … [Read more...] about Marinomed gets Chinese patent for polymer used in anti-viral nasal spray
OptiNose announces Phase 3 data, grant
OptiNose has announced Phase 3 results from a study of its sumatriptan nasal powder for the treatment of migraine, as well as a grant from the Research Council of Norway to study nasal delivery of oxytocin for the treatment of autism spectrum disorders. According to OptiNose US, the Phase 3 TARGET study found that 42% of patients with moderate to severe migraines … [Read more...] about OptiNose announces Phase 3 data, grant
Pearl Therapeutics gets funding for Phase 3 studies of PT003
Pearl Therapeutics has raised $65 million from current investors to enable initiation of Phase 3 trials for its PT003 glycopyrrolate (GP)/formoterol fumarate (FF) MDI for the treatment of COPD, the company says. This round of financing brings the total to $167.5 million since 2007. Pearl CEO Chuck Bramlage said, “Through our comprehensive Phase 2 program, Pearl … [Read more...] about Pearl Therapeutics gets funding for Phase 3 studies of PT003
Boehringer Ingelheim to double production at Respimat facility
Boehringer Ingelheim has announced an €85 million expansion to the BI microParts GmbH inhaler manufacturing facililty in Dortmund, Germany meant to double its annual production of Respimat inhalers to 44 million by 2015. Filling of the Respimat inhalers takes place in Ingelheim. The company says that it will need to add more than 100 new hires to the existing 450 … [Read more...] about Boehringer Ingelheim to double production at Respimat facility
Team Consulting, Lab Automate win awards
Two companies that provide services to OINDP developers and manufacturers have been awarded major prizes recently. The 2012 British Engineering Excellence Awards recognized device design experts Team Consulting as "Consultancy of the Year." Criteria for the award include, "the speed with which projects have been delivered," "the range of technologies handled by the … [Read more...] about Team Consulting, Lab Automate win awards